Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
GRCE Grace Therapeutics Inc.
- Stocks
- Healthcare
- NASDAQ: GRCE
Price (delayed)
$2.8
Market cap
$28.39M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.16
Enterprise value
$17.34M
Highlights
The debt has shrunk by 100% YoY
The EPS has surged by 77% year-on-year but it has declined by 15% since the previous quarter
Grace Therapeutics's net income has soared by 66% YoY but it has decreased by 15% from the previous quarter
Grace Therapeutics's quick ratio has shrunk by 61% YoY
The company's equity fell by 19% YoY and by 7% QoQ
Key stats
What are the main financial stats of GRCE
Market
Valuations
Earnings
Shares outstanding
10.14M
Market cap
$28.39M
Enterprise value
$17.34M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.54
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$16.76M
Net income
-$13.37M
EBIT
-$16.92M
EBITDA
-$16.92M
Free cash flow
-$14.06M
Per share
Balance sheet
Liquidity
EPS
-$1.16
EPS diluted
-$1.16
Free cash flow per share
-$1.22
Book value per share
$5.14
Revenue per share
$0
TBVPS
$1.04
Total assets
$61.22M
Total liabilities
$9.09M
Debt
$0
Equity
$52.14M
Working capital
$9.97M
Debt to equity
0
Current ratio
6.06
Quick ratio
5.76
Net debt/EBITDA
0.65
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-19.8%
Return on equity
-23.3%
Return on invested capital
N/A
Return on capital employed
-28.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GRCE stock price
How has the Grace Therapeutics stock price performed over time
Intraday
-7.28%
1 week
3.32%
1 month
49.73%
1 year
-3.11%
YTD
-25.13%
QTD
22.81%
Financial performance
How have Grace Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$16.76M
Net income
-$13.37M
Gross margin
N/A
Net margin
N/A
Grace Therapeutics's net income has soared by 66% YoY but it has decreased by 15% from the previous quarter
GRCE's operating income has soared by 65% year-on-year but it is down by 4.1% since the previous quarter
Price vs fundamentals
How does GRCE's price correlate with its fundamentals
Growth
What is Grace Therapeutics's growth rate over time
Valuation
What is Grace Therapeutics stock price valuation
P/E
N/A
P/B
0.54
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has surged by 77% year-on-year but it has declined by 15% since the previous quarter
The stock's P/B is 40% below its 5-year quarterly average of 0.9 and 10% below its last 4 quarters average of 0.6
The company's equity fell by 19% YoY and by 7% QoQ
Efficiency
How efficient is Grace Therapeutics business performance
The ROA has soared by 61% YoY but it has contracted by 21% from the previous quarter
The ROE has soared by 60% YoY but it has contracted by 21% from the previous quarter
Dividends
What is GRCE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GRCE.
Financial health
How did Grace Therapeutics financials performed over time
Grace Therapeutics's quick ratio has shrunk by 61% YoY
The company's current ratio has shrunk by 60% YoY
The debt is 100% lower than the equity
The debt has shrunk by 100% YoY
The company's equity fell by 19% YoY and by 7% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.